Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Vaccine compositions

A technology of composition and medicine, which is applied in the field of tumor treatment and can solve problems such as missing parts

Inactive Publication Date: 2011-02-02
AGIRX
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this construct consists of truncated segments of human IL-11R and IL-11 and thus lacks naturally occurring portions of the respective receptors and cytokines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine compositions
  • Vaccine compositions
  • Vaccine compositions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0110] Example 1: Hyper-IL-6 (H6) Enhances T Cell Proliferative Response in Allogeneic Mixed Tumor-Lymphocyte Reaction (AMTLR)

[0111] Irradiated tumor cells were mixed with unprimed allogeneic lymphocytes in the presence or absence of IL-6 (1 ng / ml) or purified H6 (1 ng / ml). three days later, with 3 T cell proliferation was measured by H-thymidine incorporation and expressed as counts per minute (cpm). For the results of this experiment, see figure 1 .

[0112] Columns 1-3 show spontaneous proliferation of T cells, ie proliferation in the absence of tumor cell stimulation. Clearly, spontaneous proliferation of T cells was not significantly increased (columns 1-3), regardless of whether IL-6 (column 2) or H6 (column 3) was added to the mixture.

[0113] Columns 4-6 show the results of T cell proliferation in response to allogeneic tumor cells. T cells showed very strong proliferation in the presence of allogeneic tumor cells (column 4). The addition of IL-6 had no sign...

Embodiment 2

[0114] Example 2: T cell proliferation in an allogeneic mixed tumor-lymphocyte response is dependent on IL-2

[0115] Irradiated tumor cells were mixed with unprimed allogeneic lymphocytes in the presence or absence of IL-6 (1 ng / ml) or purified H6 (1 ng / ml) and anti-IL-2 antibody (1 μg / ml). Cells are mixed. three days later, with 3 T cell proliferation was measured by the H-thymidine incorporation method and expressed as cpm. For the results of this experiment, see figure 2 .

[0116] figure 2 Middle columns 1-3 show the results of T cell proliferation in response to allogeneic tumor cells in the absence of anti-IL-2 antibodies. The results of this experiment and figure 1 The results in columns 4-6 are almost the same. As shown in Example 1, T cells showed very strong proliferation in the presence of allogeneic tumor cells ( figure 2 column 1). The addition of IL-6 had no significant effect on the proliferation of T cells ( figure 2 column 2). The addition of ...

Embodiment 3

[0118] Example 3: Hyper-IL-6 Enhances IL-2 and IFN-γ Production by T Cells in Allogeneic Mixed Tumor-Lymphocyte Reaction (AMTLR)

[0119] This example describes the evaluation of the immunostimulatory potential of hyper IL-6 (H6) in an allogeneic mixed tumor-lymphocyte response. The obtained results indicate that super IL-6 enhances the immunostimulatory potential of allogeneic melanoma cells. Moreover, ultra-IL-6 is not only more potent than IL-6, but also exhibits qualitatively different biological activities. Compared with native IL-6, a known Th2 inducer, hyper-IL-6 appears to reduce the expression of IL-10 and increase the amount of IFN-γ and IL-2 produced by peripheral blood lymphocytes (PBLC), which is a Th1 characteristics of the response.

[0120] Test sample : A375 melanoma cells and their derivatives A375-H6 cells; PBLC isolated from healthy volunteers.

[0121] Media, Reagents and Equipment : FBS (GIBCO / Invitrogen), PBS (GIBCO / Invitrogen), DMEM (GIBCO / Invitr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to tumour therapy. In particular, the present invention relates to vaccine compositions comprising allogenic cells modified with hypercytokines for the treatment of cancer in general and for the treatment of melanoma in particular.

Description

technical field [0001] The present invention relates to tumor therapy. In particular, the present invention relates to vaccine compositions comprising allogeneic cells modified with supracytokine for use in the treatment of cancer in general, and in particular for the treatment of melanoma. Background technique [0002] Cytokines and cytokine receptors [0003] IL-11 and IL-6, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1) all belong to the family of hematopoietic cytokines (named IL-6-type or gp130 cytokines), which share structural similarities and a common receptor subunit (gp130) (Bazan et al., 1990). Although each IL-6-type cytokine requires a specific (unique) receptor complex, at least one molecule of gp130 is always utilized. Ligands (IL-6, IL-11, CNTF) first specifically bind their α non-signaling receptor subunits and then recruit signaling receptor chains. IL-6 and IL-11 use the gp130 homodimer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61P35/00A61K38/20A61K39/00
CPCA61K39/0011A61K2039/5156A61K2039/55527A61K2039/5152A61K2039/55516A61K39/39A61P1/02A61P1/04A61P1/16A61P1/18A61P11/00A61P13/08A61P13/10A61P13/12A61P15/00A61P17/00A61P25/00A61P27/02A61P35/00A61P43/00A61K2039/876A61K2039/80
Inventor 安杰伊·马茨凯维奇
Owner AGIRX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com